The first-line pharmacotherapy recommended for DKD in the clinical guidelines includes sodium-glucose cotransporter 2 (SGLT2) inhibitor, metformin, renin-angiotensin-system (RAS) blockade, and moderate- or high-intensity statin. The gene discussed is SLC5A2; the disease is diabetic kidney disease.